|  |          | Prior Authorization        | on Form |          |  |  |
|--|----------|----------------------------|---------|----------|--|--|
|  |          |                            |         |          |  |  |
| CAREFIRST  |          |                            |         |          |  |  |
| Oriahnn  |          |                            |         |          |  |  |
| This fax machine is located in a secure location as required by HIPAA regulations.<br>Complete/review information, sign and date. Fax signed forms to CVS/Caremark at <b>1-888-836-0730</b> .<br>Please contact CVS/Caremark at <b>1-800-294-5979</b> with questions regarding the prior authorization process.<br>When conditions are met, we will authorize the coverage of Oriahnn. |          |                            |         |          |  |  |
| Drug Name (select from list of drugs shown)  |          |                            |         |          |  |  |
|  |          |                            |         |          |  |  |
| Oriahnn (elagolix-estradiol-norethindrone acetate)   |          |                            |         |          |  |  |
| Quantity   | Fred     | luency                     |         | Strength |  |  |
| Route of Adminis   | stration | Expected Length of Therapy |         |          |  |  |
| Patient Information  | on       |                            |         |          |  |  |
| Patient Name:  |          |                            |         |          |  |  |
| Patient ID:  |          |                            |         |          |  |  |
| Patient Group No   | D.:      |                            |         |          |  |  |
| Patient DOB:   |          |                            |         |          |  |  |
| Patient Phone:   |          |                            |         |          |  |  |
| Prescribing Phys   | ician    |                            |         |          |  |  |
| Physician Name:  |          |                            |         |          |  |  |
| Physician Phone  | :        |                            |         |          |  |  |
| Physician Fax:   |          |                            |         |          |  |  |
| Physician Address:   |          |                            |         |          |  |  |
| City, State, Zip:  |          |                            |         |          |  |  |
| <b>.</b>   |          |                            | •       |          |  |  |
| Diagnosis:   |          | ICD Co                     | ode:    |          |  |  |
| Comments:  |          |                            |         |          |  |  |
|  |          |                            |         |          |  |  |
| Please circle the appropriate answer for each question.  |          |                            |         |          |  |  |
| 1. Is the requested drug being prescribed for the Y N  |          |                            |         |          |  |  |
| management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in a premenopausal patient?   |          |                            |         |          |  |  |
| [If no, then no further questions.]  |          |                            |         |          |  |  |
| 2. Has the patient previously received treatment with an Y N   |          |                            |         |          |  |  |
| elagolix-containing product (e.g., Oriahnn, Orilissa) or a relugolix-containing product (e.g., Myfembree)?   |          |                            |         |          |  |  |
| [If no, then no further questions.]  |          |                            |         |          |  |  |
| <ol> <li>Has the patient already received any of the following: A) Y N<br/>Greater than or equal to 24 cumulative months of treatment</li> </ol>   |          |                            |         |          |  |  |

|  | with elagolix-containing products (e.g., Oriahnn, Orilissa)<br>and/or relugolix-containing products (e.g., Myfembree), B<br>Greater than or equal to 6 months of treatment with Orilis<br>200mg twice daily? |  |  |  |  |
|--|--|--|--|--|--|
|  | [If yes, then no further questions.]   |  |  |  |  |
| 4.   | 4. How many cumulative months has the patient received<br>treatment with elagolix-containing products (e.g., Oriahnn,<br>Orilissa) and/or relugolix-containing products (e.g.,<br>Myfembree)?                |  |  |  |  |
| [Note: Please check the total cumulative months of treatment.] |  |  |  |  |  |
|  | 12 months or less(if checked, no further questions)  |  |  |  |  |
|  | 13 months (if checked, no further questions)   |  |  |  |  |
|  | 14 months (if checked, no further questions)   |  |  |  |  |
|  | 15 months (if checked, no further questions)   |  |  |  |  |
|  | 16 months (if checked, no further questions)   |  |  |  |  |
|  | 17 months (if checked, no further questions)   |  |  |  |  |
|  | 18 months (if checked, no further questions)   |  |  |  |  |
|  | 19 months (if checked, no further questions)   |  |  |  |  |
|  | 20 months (if checked, no further questions)   |  |  |  |  |
|  | 21 months (if checked, no further questions)   |  |  |  |  |
|  | 22 months (if checked, no further questions)   |  |  |  |  |
|  | 23 months (if checked, no further questions)   |  |  |  |  |
|  | 24 months or greater (if checked, no further question)   |  |  |  |  |

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

## Prescriber (Or Authorized) Signature and Date